Advertisement

Topics

Varenicline vs Placebo for the Treatment of Methamphetamine Dependence

2014-08-27 03:18:03 | BioPortfolio

Summary

Methamphetamine (MA) abuse is the fastest growing drug problem in the United States and is responsible for significant public health complications, including HIV infection. As a result effective treatments for MA dependence are urgently needed. There are currently no efficacious medications for MA dependence, although results from preliminary randomized trials of bupropion for MA dependence found bupropion to be more effective than placebo, but only among subgroups of participants, including those with lower frequency of MA use at baseline. A growing body of preclinical and clinical studies suggest that cholinergic mechanisms play an important role in the neurobiology of MA and other stimulant dependence, such as nicotine dependence. Mechanistically, cholinergic medications may alleviate MA-associated cognitive dysfunction, thereby improving outcomes of treatment for MA dependence. Varenicline is a partial agonist at α4β2 nicotinic receptors and a full agonist at α7 nicotinic receptors that has been approved as an anti-cigarette smoking medication. In order to assess the potential efficacy of varenicline for methamphetamine dependence, we will perform a clinical trial to assess if varenicline compared to placebo results in greater:

1. reductions in methamphetamine use;

2. treatment retention;

3. MA withdrawal symptoms;

4. reductions in ad libitum cigarette smoking; and

5. to determine if baseline cognitive function is associated with treatment outcomes regardless of treatment assignment.

Description

Methamphetamine (MA) abuse is the fastest growing drug problem in the United States and is responsible for significant public health complications, including HIV infection1. As a result effective treatments for MA dependence are urgently needed. There are currently no efficacious medications for MA dependence, although results from preliminary randomized trials of bupropion for MA dependence found bupropion to be more effective than placebo, but only among subgroups of participants, including those with lower frequency of MA use at baseline 2, 3. A growing body of preclinical and clinical studies suggest that cholinergic mechanisms play an important role in the neurobiology of MA and other stimulant dependence, such as nicotine dependence 4. Mechanistically, cholinergic medications may alleviate MA-associated cognitive dysfunction, thereby improving outcomes of treatment for MA dependence 5. Varenicline is a partial agonist at α4β2 nicotinic receptors and a full agonist at α7 nicotinic receptors that has been approved as an anti-cigarette smoking medication. In order to assess the potential efficacy of varenicline for methamphetamine dependence, we will perform a clinical trial to assess the following aims:

1. To determine if varenicline results in significantly greater reductions in methamphetamine use than placebo, as determined via the proportion of methamphetamine-free urine specimens provided by participants throughout treatment, when provided to methamphetamine dependent participants in conjunction with cognitive behavioral therapy.

Exploratory Aim 1a. To determine whether reductions in methamphetamine use with varenicline versus placebo are greater among methamphetamine dependent participants with baseline light MA use (MA use on 18 or fewer of the past 30 days at baseline) versus heavy MA use (MA use on more than 18 of the past 30 days).

Exploratory Aim 1b. To determine if varenicline results in a greater proportion of methamphetamine dependent participants achieving methamphetamine abstinence defined as self-reported MA abstinence, confirmed via urine drug screens (all available urine drug screens are MA-metabolite free and at least one urine drug screen available per week and no more than two missed visits between urine drug screens) during the final two weeks of the study medication period (weeks 7 and 8) relative to placebo when provided in conjunction with cognitive behavioral therapy.

2. To determine if varenicline results in significantly greater treatment retention than placebo among MA dependent participants when provided in conjunction with cognitive behavioral therapy.

3. To determine if varenicline results in significantly greater reductions in MA withdrawal symptoms than placebo, as determined via the Amphetamine Cessation Symptoms Assessment Scale (ACSA), among MA dependent participants when provided in conjunction with cognitive behavioral therapy.

4. To determine if baseline cognitive function, as determined via our cognitive battery is associated with subsequent treatment outcomes (MA use and retention) among MA dependent participants overall regardless of treatment group assignment.

Aim 4a. To determine if treatment outcomes with varenicline versus placebo differ among participants with baseline higher versus lower cognitive function, as assessed via our cognitive battery.

5. To determine if varenicline results in greater reductions in ad libitum cigarette smoking compared to placebo among MA dependent participants.

Exploratory Aim 5a. To determine whether reductions in methamphetamine use correlate significantly with reductions in ad libitum cigarette smoking among cigarette smoking MA dependent participants who receive varenicline as compared to placebo.

We will also perform additional exploratory analyses examining whether (1) variation in genes related to MA abuse and/or response to varenicline, such as dopaminergic (e.g. COMT, DAT, DRD2, and VMAT2) and/or cholinergic (e.g. CHRNA3-CHRNA5-CHRNB4 gene cluster) signaling system genes baseline frequency of methamphetamine use and/or treatment outcomes (MA use, retention). To address these aims, we will recruit 70 MA dependent participants who will be randomized to receive treatment with varenicline (n=35) or placebo (n=35) for 8 weeks, in combination with cognitive behavioral therapy, followed by 4 weeks of follow up observation.

As in other pilot trials conducted under the UCLA Medication Development P50 Center, the study is powered to identify effects of a putative medication that has moderate or greater effect size along a set of a priori specified hypotheses in order to determine whether there is a signal for the medication that can be followed with an adequately powered confirmatory study. The primary aim comparing potential reductions in MA use, as determined via thrice-weekly urine drug screen results, will be used to determine the power for this study (See Power Analysis below). Results of this study have the potential to provide additional safety data and to yield preliminary evidence that may support a fully powered late Phase II trial of the efficacy of varenicline for the treatment of methamphetamine dependence. Findings also have potential to provide insights into the influence of cognitive dysfunction, and medications with potential cognitive enhancing effects, on the pathogenesis of MA dependence and treatment outcomes.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Conditions

Methamphetamine Dependence

Intervention

Varenicline, Placebo

Location

UCLA Vine Street Clinical Research Site
Los Angeles
California
United States
90038

Status

Recruiting

Source

National Institute on Drug Abuse (NIDA)

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:18:03-0400

Clinical Trials [598 Associated Clinical Trials listed on BioPortfolio]

Varenicline-Methamphetamine Interaction Study

The primary aim of the study is to determine the safety and tolerability of treatment with Varenicline in methamphetamine-dependent volunteers. The investigators also seek to determine the...

Aripiprazole for Methamphetamine Dependence: Double Blind Placebo Trial

The purpose of this study is to test whether treatment with Aripiprazole leads to a reduction in methamphetamine craving and use in patients diagnosed with methamphetamine dependence. Pat...

Phase 2, Double-Blind, Placebo-Controlled Trial of Bupropion for Methamphetamine Dependence

This study is to assess the efficacy of bupropion in reducing methamphetamine use in subjects with methamphetamine dependence who report using methamphetamine 18 or less days during the 30...

Bupropion in the Treatment of Methamphetamine Dependence

Methamphetamine dependence is a significant drug use disorder in the Midwest. While a number of psychosocial and pharmacological treatments have been studied, no specific treatments for m...

Effects of Modafinil in Methamphetamine Dependence

Methamphetamine dependence is a serious public health problem with no pharmacologic treatments currently available. Relapse rates are high in this population. Exposure to cues previously...

PubMed Articles [2445 Associated PubMed Articles listed on BioPortfolio]

Varenicline treatment for methamphetamine dependence: A randomized, double-blind phase II clinical trial.

Previous studies have suggested that varenicline, an α4β2 nicotinic receptor partial agonist, and α7 nicotinic receptor full agonist, may be effective for the treatment of methamphetamine (MA) depe...

Methamphetamine dependence with and without psychotic symptoms: A multi-modal brain imaging study.

Methamphetamine dependence can lead to psychotic symptoms which may be mediated by frontal, striatal, limbic, and thalamic regions. There are few neuroimaging data that allow comparison of individuals...

Predicting smoking abstinence with biological and self-report measures of adherence to varenicline: Impact on pharmacogenetic trial outcomes.

Adherence to pharmacotherapies for tobacco dependence, such as varenicline, is necessary for effective treatment. The relationship between varenicline adherence, determined by commonly used indirect (...

Effects of varenicline on subjective craving and relative reinforcing value of cigarettes.

Varenicline is an FDA approved medication for the treatment of nicotine dependence. While the efficacy and safety of this medication have been demonstrated, success rates remain low, and efforts to un...

CHN2 Promoter Methylation Change May Be Associated With Methamphetamine Dependence.

Methamphetamine (MA) abuse is becoming increasingly serious in China. The mechanism of MA dependence remains unclear. CHN2 gene encodes chimeric protein-2 that regulate axonal pruning via the Rac-GTPa...

Medical and Biotech [MESH] Definitions

Strong dependence, both physiological and emotional, upon heroin.

Strong physiological and emotional dependence on OPIUM.

Strong dependence, both physiological and emotional, upon morphine.

A benzazepine derivative that functions as an ALPHA4/BETA2 NICOTINIC RECEPTOR partial agonist. It is used for SMOKING CESSATION.

Misunderstanding among individuals, frequently research subjects, of scientific methods such as randomization and placebo controls.

More From BioPortfolio on "Varenicline vs Placebo for the Treatment of Methamphetamine Dependence"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Public Health
Alternative Medicine Cleft Palate Complementary & Alternative Medicine Congenital Diseases Dentistry Ear Nose & Throat Food Safety Geriatrics Healthcare Hearing Medical Devices MRSA Muscular Dyst...


Searches Linking to this Trial